DEVELOPMENT AND MANUFACTURE OF MICROBIAL-DERIVED BIOPHARMACEUTICALS
Richter-Helm is a leading and steadily growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with two cGMP-compliant manufacturing facilities in Germany.
We specialize in products derived from bacteria and yeasts. Over the past 30 years we gained substantial experience in the development and manufacture of product types that include recombinant proteins and peptides, antibody-like scaffolds (VHH/ Nanobodies, Fab fragments), plasmid DNA, and bacterial vaccines.
We move our clients projects forward: flexible, transparent, fast
Our Microbial Capabilities
Our company in numbers
How Richter-Helm Overcomes the Challenges of the Covid-19 Pandemic
CORONA WAR EIN BOOSTER FÜR DIE BIOTECHNOLOGIE-BRANCHE.
Die Richter-Helm Biologics GmbH & Co. KG aus Hamburg ist seit über 30 Jahren ein Lohnhersteller für biopharmazeutische Produkte. Mit großer Expertise im Bereich der DNA-Impfstoffe war das Unternehmen während der Pandemie für große US Entwicklungsunternehmen ein wichtiger Produktionspartner.
Mit neuen Produktionsanlagen will das Unternehmen jetzt seine Kapazitäten für die kommenden Jahre weiter ausbauen.
Plasmids are circular, double-stranded DNA molecules of various sizes originally found in bacteria, archaea and eukaryotic yeast. They replicate independently of chromosomal DNA and are easily genetically modified. Plasmids can be used for a variety of pharmaceutical purposes: as the active pharmaceutical ingredient (API) in DNA vaccines to prevent viral infections or cancer development; as critical raw material, starting material or ancillary material for viral vector production; or as template for mRNA-based products.
Developing and manufacturing microbial-derived biopharmaceutical products require deep expertise and reliable solutions that can guide a project to success while meeting evolving industry standards. To this end, pharmaceutical companies need expert partners capable of bringing promising cures to the market on time, regardless of scale.
In recent years, customer requirements for contract development and manufacturing organization (CDMO) services have changed. CDMOs have developed into partners, consultants, and providers of specific services, all preferably coming from a single source. Richter-Helm is one driver of a transparent, flexible, guided, and solution-oriented way of partnership, offering its clients a full-service approach along the entire journey from gene to finished product.
Richter-Helm´s Biomanufacturing Facility Expansion progress: inauguration of the new office building
Richter-Helm BioLogics has reached a further and important construction milestone during the expansion of its production site in Bovenau. We officially and ceremoniously inaugurated the new office building on May 31, 2023 together with the mayor of Bovenau, Mr. Ambrock, two years after the groundbreaking ceremony.
Oslo, Norway, December 19, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.